Alteon other research news

ALTN announced that it has identified a new compound, ALT-946, which it is developing to treat diabetic complications.

The drug evolved from a chemical modification of the company's lead compound, pimagedine, which is designed to inhibit or block the formation of advanced glycosylation end-products. A.G.E.s are abnormal glucose-protein complexes that can lead to complications of diabetes and age-related diseases, such as kidney disease, atherosclerosis, retinopathy, and cataracts. ...